Retraction notice to “Safety and Efficacy Of Sorafenib In Patients With Castrate Resistant Prostate Cancer: A Phase II Study” [Urologic Oncology: Seminars and Original Investigations 28 (2010) 21–27]
- DOI
- 10.1016/j.urolonc.2026.10.003
- Published
- 2026-11
- Container
- Urologic Oncology: Seminars and Original Investigations
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.urolonc.2026.10.003,
title = {Retraction notice to “Safety and Efficacy Of Sorafenib In Patients With Castrate Resistant Prostate Cancer: A Phase II Study” [Urologic Oncology: Seminars and Original Investigations 28 (2010) 21–27]},
author = {Mohammad Reza Safarinejad},
year = {2026},
journal = {Urologic Oncology: Seminars and Original Investigations},
doi = {10.1016/j.urolonc.2026.10.003},
url = {https://doi.org/10.1016/j.urolonc.2026.10.003}
}RIS
TY - JOUR TI - Retraction notice to “Safety and Efficacy Of Sorafenib In Patients With Castrate Resistant Prostate Cancer: A Phase II Study” [Urologic Oncology: Seminars and Original Investigations 28 (2010) 21–27] AU - Mohammad Reza Safarinejad PY - 2026 JO - Urologic Oncology: Seminars and Original Investigations DO - 10.1016/j.urolonc.2026.10.003 UR - https://doi.org/10.1016/j.urolonc.2026.10.003 ER -
APA
Safarinejad, M. R. (2026). Retraction notice to “Safety and Efficacy Of Sorafenib In Patients With Castrate Resistant Prostate Cancer: A Phase II Study” [Urologic Oncology: Seminars and Original Investigations 28 (2010) 21–27]. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2026.10.003
Source records
- crossref · retrieved 2026-11-09T21:12:43.090Z